Royalty Pharma to Acquire Up to $950 Million Royalty Interest From BeOne in Amgen’s Lung Cancer Drug Imdelltra, Excluding China Sales

Royalty Pharma has agreed to acquire royalty rights from BeOne Medicines on Amgen's lung cancer drug Imdelltra for up to $950 million, excluding sales in China. The deal includes an upfront payment of $885 million, with an additional $65 million payable within 12 months if BeOne opts to sell remaining royalties. Through this transaction, Royalty Pharma will gain a 7% share of global net sales from Imdelltra, a treatment for small cell lung cancer. BeOne Medicines will continue to collect royalties from the drug outside of China. The acquisition represents a strategic investment in oncology by Royalty Pharma.